RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
10.1038/s41388-020-01567-7
Saved in:
Main Authors: | Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jurgen, Alic, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany, Weinstock, David M, Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nizetic, Dean |
---|---|
Other Authors: | DEAN'S OFFICE (MEDICINE) |
Format: | Article |
Language: | English |
Published: |
SPRINGERNATURE
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/228999 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Frequent cases of RAS-mutated down syndrome acute lymphoblastic leukaemia lack JAK2 mutations
by: Nikolaev, Sergey I., et al.
Published: (2014) -
Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq
by: Li, Zhenhua, et al.
Published: (2020) -
BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia
by: Jiang, N., et al.
Published: (2014) -
The association between HLA-E gene and genetic susceptibility of nasopharyngeal carcinogenesis
by: Ingorn Kimkong
Published: (2008) -
A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome
by: Alakbarzade, Vafa, et al.
Published: (2020)